Cara Therapeutics | CARA - Assets


Cara Therapeutics reported $32.07M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
Assertio Holdings USD 319.77M 46M Sep/2025
Cara Therapeutics USD 32.07M 6.95M Dec/2025
Cassava Sciences USD 108.37M 9.99M Mar/2026
Chugai Pharma JPY 2.27T 203.49B Mar/2026
Cipla INR 424.96B 23.32B Mar/2026
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 156.57M 58.73M Dec/2025
CSL USD 37.9B 1.5B Dec/2025
Grifols EUR 23.15B 142.7M Dec/2025
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Pacira USD 1.21B 56.38M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
RedHill Biopharma USD 25.34M 6.97M Dec/2025
Supernus Pharmaceuticals USD 1.5B 48.08M Mar/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025